TG Therapeutics (TGTX) has a very strong forecast
What’s up with TG Therapeutics?
TG Therapeutics (TGTX) opened at $16.01, which means the stock is up 26.00% from yesterday’s closing price of 12.46. Today, the company has a high of $16.38 and a low of $14.60. The company has a market cap of $1.72 billion with a 52-week high of $16.38 and a 52-week low of $4.95.
What about the future for TG Therapeutics?
The high forecast for TG Therapeutics is 39.00 while the low is 18.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. TG Therapeutics has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future.. Based on this information TGTX seems to be a safe buy.
About TG Therapeutics
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.